Sunovion seeks FDA approval for COPD treatment

<?EM-dummyText [Drophead goes here] ?>

Sunovion Pharmaceuticals Inc. of Marlborough said Friday it applied for US regulatory approval of a drug-device combination to treat airflow obstruction in patients with chronic obstructive pulmonary disease, or COPD. The company, a subsidiary of Japan's Sumitomo Dainippon Pharma Group, is asking the Food and Drug Administration to give its OK for a product called SUN-101/eFlow, which combines a drug and a device called a nebulizer that delivers it in a spray. In April, Sunovion reported positive clinical results for the product, which was tested in a clinical trial that enrolled 653 patients with COPD at 45 sites across the United States. More than 15 million American adults have been diagnosed with COPD.

Robert Weisman

Robert Weisman can be reached at robert.weisman@globe.com. Follow him on Twitter @GlobeRobW.